Enzychem Lifesciences announced that it has completed patient enrollment in Stage 2 of its Phase 2 clinical trial of EC-18 in chemoradiation induced oral mucositis (CRIOM). Stage 2 of the Phase 2 study successfully enrolled 80 subjects, evaluating both safety and efficacy. Database Lock (DBL) is expected in near end of Second Quarter 2021. After the completion of DBL, data analysis including drafting top-line summaries will begin. EC-18, the company's lead investigational candidate, is a novel, first-in-class, immunomodulator, which facilitates the resolution of inflammation and enhances anti-infective and tissue-healing pathways of the immune system. Enzychem received Fast Track Designation from the U.S. Food and Drug Administration for the Phase 2 study evaluating EC-18 in CRIOM. The Phase 2, randomized, double-blind, placebo-controlled, 2-stage study evaluated EC-18 in patients with squamous cell cancers of the mouth, oropharynx, hypopharynx and nasopharynx who plan to receive standard fractionated IMRT-delivered radiotherapy with concomitant chemotherapy (cisplatin). Stage 2 enrolled 80 patients who will be randomized in a 1:1 scheme to receive either placebo or 2000 mg of EC-18 as determined by independent Data Safety Monitoring Board in Stage 1.